|
|
|
|
|
Last Trade
|
Last Trade:
$8.68
|
Change:
0.27 (3.21%)
|
Trade Time:
Dec 06
|
Market Cap:
$199.55M
|
|
|
|
|
|
|
Description of Business
|
|
We are a biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for debilitating
liver diseases. We focus on diseases for which the unmet medical need is high
and the biology for treatment is clear. Our pipeline consists of two
clinical-stage product candidates with mechanisms of action that have potential
utility across a wide range of orphan liver diseases. We are initially
developing maralixibat for the treatment of pediatric patients with progressive
familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS.
Based on improvements in pruritus, or itching, and other disease markers
observed in Phase 2 clinical trials, we commenced enrollment in the Phase 3
MARCH clinical trial in PFIC in the second quarter of 2019 and are planning to
initiate a Phase 3 clinical trial in ALGS in the first half of 2020.
|
|
|
|